Drug updated on 11/14/2023

Dosage FormInjection (intravenous; 300 mg)
Drug ClassKinase inhibitors
Ongoing and Completed


  • Indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer.

Product Monograph / Prescribing Information

Document TitleYearSource
Cosela (trilaciclib) Prescribing Information.2023G1 Therapeutics, Inc. Durham, NC

Systematic Reviews / Meta-Analyses